# Accent Therapeutics

Source: https://onco.cc/companies/accent-therapeutics/  
OnCo record `accent-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Accent Therapeutics makes tablets aimed at cancers whose cells carry the wrong number of chromosomes, a weakness that healthy cells do not share. Its lead medicine is being tested in ovarian and squamous lung cancer.

## Summary

Accent Therapeutics, based in Lexington, Massachusetts, develops oral small molecules against dependencies created by genomic and chromosomal instability. Its lead programme ATX-295 is an inhibitor of the mitotic kinesin KIF18A, which the company describes as selectively essential in tumours with high chromosomal instability; it is in a phase 1/2 trial (NCT06799065) in advanced or metastatic solid tumours including high-grade serous ovarian cancer and squamous non-small cell lung cancer, and the company states it keeps full worldwide rights to the programme. A second clinical programme, ATX-559, an oral inhibitor of the RNA helicase DHX9, entered a first-in-human trial in molecularly defined cancers (NCT06625515), which the registry lists as terminated. The company reported FDA Fast Track designation for both ATX-295 and ATX-559 in April 2025, and in October 2025 announced that Boehringer Ingelheim had obtained a preclinical oncology programme from it. Its first registered cancer trial, NCT06625515, was posted on ClinicalTrials.gov in October 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Lexington, MA
- Type: biotech
- Website: https://accenttx.com/

## Notes

- Founding year not stated on the company website, read on 29 October 2026.
- No financing round is recorded because no company release stating an amount was read.
- Trial status for NCT06625515 (terminated) and NCT06799065 (recruiting) comes from the ClinicalTrials.gov records read on 29 October 2026; the reason for termination was not read.

## Sources

- Official website: https://accenttx.com/
- Approach and pipeline: https://accenttx.com/approach-pipeline/
- ClinicalTrials.gov: phase 1/2 trial of ATX-295 (NCT06799065): https://clinicaltrials.gov/study/NCT06799065
- ClinicalTrials.gov: first-in-human trial of ATX-559 (NCT06625515): https://clinicaltrials.gov/study/NCT06625515

## Connected records

- cancers: [High-grade serous ovarian cancer](https://onco.cc/cancers/high-grade-serous-ovarian-cancer/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/), [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- targets: [DHX9](https://onco.cc/targets/dhx9/)

---
JSON: https://onco.cc/api/v1/entities/accent-therapeutics.json